Intralink-Spine expands clinical trials for injectable product

Spinal device company Intralink-Spine has expanded clinical trials of its Rejuve device in Australia, according to a July 14 news release.

Advertisement

Three things to know:

1. Rejuve is an injectable device that strengthens and stabilizes the degenerated disc.

2. Performed on an outpatient basis, Rejuve can be used as an adjunct or replacement to surgeries, including discectomies, spinal fusions and spinal implants.

3. The device is intended for the treatment of degenerative disc disease, lumbar pain and associated spinal diseases.

More articles on devices:
Setting spine practices up for success post-pandemic: 5 industry insights
UAMS begins data gathering initiative with spine patients
3 spine surgeons on the move in June

Advertisement

Next Up in Spinal Tech

  • Zavation Medical has acquired ChoiceSpine, and Derek Kuyper will be CEO of the combined company, according to a Feb. 26…

  • Carlsmed saw significant gains in fourth-quarter and 2025 revenue, according to financial results posted Feb. 25. Five things to know:…

Advertisement

Comments are closed.